{"pmid":32474398,"title":"Impact of the Covid-19 pandemic and lung transplantation program in France.","text":["Impact of the Covid-19 pandemic and lung transplantation program in France.","Respir Med Res","Picard, C","Le Pavec, J","Tissot, A","32474398"],"journal":"Respir Med Res","authors":["Picard, C","Le Pavec, J","Tissot, A"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474398","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.resmer.2020.100758","keywords":["covid 19","drug shortage","lung transplantation","sars-cov-2","telemedicine"],"locations":["France"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Prevention"],"weight":1,"_version_":1668341932621824000,"score":9.490897,"similar":[{"pmid":32446652,"title":"Global drug shortages due to COVID-19: Impact on patient care and mitigation strategies.","text":["Global drug shortages due to COVID-19: Impact on patient care and mitigation strategies.","Coronavirus disease 2019 (COVID-19) arising from Wuhan, China, is currently outbreaking worldwide. The World Health Organization (WHO) has declared COVID-19 to be a global pandemic. COVID-19 could cause a wide range of symptoms ranging from self-limiting fever, sore throat, and cough to more severe symptoms that could lead to acute respiratory distress syndrome. As a result of the lockdown and increased demand, drug shortages could become a growing global issue. This article aims to shed light on the potential impact of drug shortages as a result of this pandemic on patient outcomes and the role of pharmacists and pharmacy policymakers in alleviating this emerging problem.","Res Social Adm Pharm","Badreldin, Hisham A","Atallah, Bassam","32446652"],"abstract":["Coronavirus disease 2019 (COVID-19) arising from Wuhan, China, is currently outbreaking worldwide. The World Health Organization (WHO) has declared COVID-19 to be a global pandemic. COVID-19 could cause a wide range of symptoms ranging from self-limiting fever, sore throat, and cough to more severe symptoms that could lead to acute respiratory distress syndrome. As a result of the lockdown and increased demand, drug shortages could become a growing global issue. This article aims to shed light on the potential impact of drug shortages as a result of this pandemic on patient outcomes and the role of pharmacists and pharmacy policymakers in alleviating this emerging problem."],"journal":"Res Social Adm Pharm","authors":["Badreldin, Hisham A","Atallah, Bassam"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32446652","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.sapharm.2020.05.017","keywords":["covid-19","coronavirus","drug shortage","pandemic","pharmacist","policymaker"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1667698385886380032,"score":61.50334},{"pmid":32467176,"title":"CONTROLS TO MINIMIZE DISRUPTION OF THE PHARMACEUTICAL SUPPLY CHAIN DURING THE COVID-19 PANDEMIC.","text":["CONTROLS TO MINIMIZE DISRUPTION OF THE PHARMACEUTICAL SUPPLY CHAIN DURING THE COVID-19 PANDEMIC.","This article reviews currently available scientific literature related to the epidemiology, infectivity, survival, and susceptibility to disinfectants of Coronaviruses, in the context of the controls established to meet Good Manufacturing Practice regulations and guidance, and the public health guidance issued specifically to combat the Covid-19 pandemic. The possible impact of the COVID-19 pandemic on the pharmaceutical supply chain is assessed and recommendations are listed for risk mitigation steps to minimize supply disruption to pharmaceutical drug products. Areas addressed include a brief history of the COVID-19 viral pandemic, a description of the virus, the regulatory response to the pandemic, the screening of employees, the persistence on inanimate surfaces, cleaning and disinfection of manufacturing facilities, use of GMP-mandated personal protective equipment to counter the spread of the disease, the role of air changes in viral clearance, approaches to risk assessment and mitigation. Biological medicinal products have a great record of safety, yet the cell cultures used for production can be susceptible to viruses, and contamination events have occurred. Studies on SARS-CoV-1 for its ability to replicate in various mammalian cell lines used for biopharmaceutical manufacturing suggest SARS-CoV-2 poses low risk and any contamination would be detected by currently used adventitious virus testing. The consequences of the potential virus exposure of manufacturing processes, as well as the effectiveness of mitigation efforts are discussed. The pharmaceutical supply chain is complex, traversing many geographies and companies that range from large multinationals to mid and small size operations. This paper recommends practices that can be adopted by all companies, irrespective of their size, geographic location, or position in the supply chain.","PDA J Pharm Sci Technol","Cundell, Anthony M","Guilfoyle, Dennis Edward","Kreil, T R","Sawant, Anil","32467176"],"abstract":["This article reviews currently available scientific literature related to the epidemiology, infectivity, survival, and susceptibility to disinfectants of Coronaviruses, in the context of the controls established to meet Good Manufacturing Practice regulations and guidance, and the public health guidance issued specifically to combat the Covid-19 pandemic. The possible impact of the COVID-19 pandemic on the pharmaceutical supply chain is assessed and recommendations are listed for risk mitigation steps to minimize supply disruption to pharmaceutical drug products. Areas addressed include a brief history of the COVID-19 viral pandemic, a description of the virus, the regulatory response to the pandemic, the screening of employees, the persistence on inanimate surfaces, cleaning and disinfection of manufacturing facilities, use of GMP-mandated personal protective equipment to counter the spread of the disease, the role of air changes in viral clearance, approaches to risk assessment and mitigation. Biological medicinal products have a great record of safety, yet the cell cultures used for production can be susceptible to viruses, and contamination events have occurred. Studies on SARS-CoV-1 for its ability to replicate in various mammalian cell lines used for biopharmaceutical manufacturing suggest SARS-CoV-2 poses low risk and any contamination would be detected by currently used adventitious virus testing. The consequences of the potential virus exposure of manufacturing processes, as well as the effectiveness of mitigation efforts are discussed. The pharmaceutical supply chain is complex, traversing many geographies and companies that range from large multinationals to mid and small size operations. This paper recommends practices that can be adopted by all companies, irrespective of their size, geographic location, or position in the supply chain."],"journal":"PDA J Pharm Sci Technol","authors":["Cundell, Anthony M","Guilfoyle, Dennis Edward","Kreil, T R","Sawant, Anil"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32467176","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.5731/pdajpst.2020.012021","keywords":["covid-19 pandemic","sars-cov-2","drug shortage","risk assessment","risk mitigation","supply chain"],"locations":["Coronaviruses","mammalian"],"e_drugs":["guanosine 5'-monophosphorothioate"],"topics":["Prevention"],"weight":1,"_version_":1668420887218487296,"score":59.710526},{"pmid":32454983,"pmcid":"PMC7237800","title":"Sterilization plan of the used metered dose inhalers (MDI) to avoid wastage amid COVID-19 pandemic drug shortage.","text":["Sterilization plan of the used metered dose inhalers (MDI) to avoid wastage amid COVID-19 pandemic drug shortage.","Background Coronavirus is causing a shortage of critical inhalers needed by patients with Asthma and respiratory illness. Patients with Asthma are at higher risk if they tract the novel Coronavirus. As the coronavirus continues to spread, hospitals are turning to use more salbutamol MDI. Salbutamol MDI has become the line of defence for physicians in the emergency room who are treating patients with Corona Virus Disease 2019 (COVID-19) and have respiratory distress .[Hui et al 2020 ,and Center for Drug Evaluation and Research 2020] During the COVID pandemic, there has been a drastic increase in the use of MDI inhalers; therefore, it led to a decrease in availability and a break in the supply chain. Patients with Asthma are at higher risk if they tract the novel Coronavirus, and an inhaler could be a life or death for them. As the coronavirus continues to spread, hospitals are turning to use more salbutamol Metered Dose inhaler (MDI). Salbutamol MDI is now on short supply as the COVID-19 continues to spread. Salbutamol MDI has become the line of defence for physicians in the emergency room who are treating patients with COVID-19 and have respiratory distress. The current shortage of salbutamol MDI could be a result of stockpiling and hoarding of this life-saving inhaler. That had led to a critical shortage of Salbutamol MDI, and even the case shortage continues with some other alternatives such as Ipratropium MDI and even with long-acting B-agonists such as Salmeterol and Formoterol which also starting to have a limitation on ordering these agents. Coronavirus sparks fear of medication shortage. Coronavirus panic-buying also may have led to a shortage of critical inhalers. We have also got elderly patients with COPD who may need Ventolin MDI and also premature babies who may have caught Respiratory Syncytial Virus (RSV) and need salbutamol MDI to support their lungs have since been compromised, and they rely heavily on Asthma inhalers. Finding a safe and creative strategy is essential during the COVID-19 pandemic.","J Pharm Policy Pract","Elbeddini, Ali","32454983"],"abstract":["Background Coronavirus is causing a shortage of critical inhalers needed by patients with Asthma and respiratory illness. Patients with Asthma are at higher risk if they tract the novel Coronavirus. As the coronavirus continues to spread, hospitals are turning to use more salbutamol MDI. Salbutamol MDI has become the line of defence for physicians in the emergency room who are treating patients with Corona Virus Disease 2019 (COVID-19) and have respiratory distress .[Hui et al 2020 ,and Center for Drug Evaluation and Research 2020] During the COVID pandemic, there has been a drastic increase in the use of MDI inhalers; therefore, it led to a decrease in availability and a break in the supply chain. Patients with Asthma are at higher risk if they tract the novel Coronavirus, and an inhaler could be a life or death for them. As the coronavirus continues to spread, hospitals are turning to use more salbutamol Metered Dose inhaler (MDI). Salbutamol MDI is now on short supply as the COVID-19 continues to spread. Salbutamol MDI has become the line of defence for physicians in the emergency room who are treating patients with COVID-19 and have respiratory distress. The current shortage of salbutamol MDI could be a result of stockpiling and hoarding of this life-saving inhaler. That had led to a critical shortage of Salbutamol MDI, and even the case shortage continues with some other alternatives such as Ipratropium MDI and even with long-acting B-agonists such as Salmeterol and Formoterol which also starting to have a limitation on ordering these agents. Coronavirus sparks fear of medication shortage. Coronavirus panic-buying also may have led to a shortage of critical inhalers. We have also got elderly patients with COPD who may need Ventolin MDI and also premature babies who may have caught Respiratory Syncytial Virus (RSV) and need salbutamol MDI to support their lungs have since been compromised, and they rely heavily on Asthma inhalers. Finding a safe and creative strategy is essential during the COVID-19 pandemic."],"journal":"J Pharm Policy Pract","authors":["Elbeddini, Ali"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454983","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1186/s40545-020-00224-4","keywords":["covid-19","drug shortage","metered dse inhalers (mdi)","sterilization"],"locations":["Ventolin"],"e_drugs":["Ipratropium","Formoterol Fumarate","Albuterol","Salmeterol Xinafoate"],"topics":["Treatment"],"weight":1,"_version_":1667983494532300800,"score":53.066013},{"pmid":32330635,"pmcid":"PMC7194708","title":"Applying the ethical principles of resource allocation to drugs in limited supply during a public health crisis.","text":["Applying the ethical principles of resource allocation to drugs in limited supply during a public health crisis.","J Am Acad Dermatol","Kong, Ha Eun","Grant-Kels, Jane M","Stoff, Benjamin K","32330635"],"journal":"J Am Acad Dermatol","authors":["Kong, Ha Eun","Grant-Kels, Jane M","Stoff, Benjamin K"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330635","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jaad.2020.04.078","keywords":["covid-19","ethics","chloroquine","drug shortage","hydroxychloroquine","resource allocation"],"weight":0,"_version_":1666138494749114368,"score":51.105732},{"pmid":32458267,"title":"Therapeutic alternatives and strategies for drug conservation in the intensive care unit during times of drug shortage: a report of the Ontario COVID-19 ICU Drug Task Force.","text":["Therapeutic alternatives and strategies for drug conservation in the intensive care unit during times of drug shortage: a report of the Ontario COVID-19 ICU Drug Task Force.","During the coronavirus disease (COVID-19) global pandemic, urgent strategies to alleviate shortages are required. Evaluation of the feasibility, practicality, and value of drug conservation strategies and therapeutic alternatives requires a collaborative approach at the provincial level. The Ontario COVID-19 ICU Drug Task Force was directed to create recommendations suggesting drug conservation strategies and therapeutic alternatives for essential drugs at risk of shortage in the intensive care unit during the COVID-19 pandemic. Recommendations were rapidly developed using a modified Delphi method and evaluated on their ease of implementation, feasibility, and supportive evidence. This article describes the recommendations for drug conservation strategies and therapeutic alternatives for drugs at risk of shortage that are commonly used in the care of critically ill patients. Recommendations are identified as preferred and secondary ones that might be less desirable. Although the impetus for generating this document was the COVID-19 pandemic, recommendations should also be applicable for mitigating drug shortages outside of a pandemic. Proposed provincial strategies for drug conservation and therapeutic alternatives may not all be appropriate for every institution. Local implementation will require consultation from end-users and hospital administrators. Competing equipment shortages and available resources should be considered when evaluating the appropriateness of each strategy.","Can J Anaesth","Kanji, Salmaan","Burry, Lisa","Williamson, David","Pittman, Michelle","Dubinsky, Samuel","Patel, Deep","Natarajan, Sabrina","MacLean, Robert","Huh, Jin-Hyeun","Scales, Damon C","Neilipovitz, David","32458267"],"abstract":["During the coronavirus disease (COVID-19) global pandemic, urgent strategies to alleviate shortages are required. Evaluation of the feasibility, practicality, and value of drug conservation strategies and therapeutic alternatives requires a collaborative approach at the provincial level. The Ontario COVID-19 ICU Drug Task Force was directed to create recommendations suggesting drug conservation strategies and therapeutic alternatives for essential drugs at risk of shortage in the intensive care unit during the COVID-19 pandemic. Recommendations were rapidly developed using a modified Delphi method and evaluated on their ease of implementation, feasibility, and supportive evidence. This article describes the recommendations for drug conservation strategies and therapeutic alternatives for drugs at risk of shortage that are commonly used in the care of critically ill patients. Recommendations are identified as preferred and secondary ones that might be less desirable. Although the impetus for generating this document was the COVID-19 pandemic, recommendations should also be applicable for mitigating drug shortages outside of a pandemic. Proposed provincial strategies for drug conservation and therapeutic alternatives may not all be appropriate for every institution. Local implementation will require consultation from end-users and hospital administrators. Competing equipment shortages and available resources should be considered when evaluating the appropriateness of each strategy."],"journal":"Can J Anaesth","authors":["Kanji, Salmaan","Burry, Lisa","Williamson, David","Pittman, Michelle","Dubinsky, Samuel","Patel, Deep","Natarajan, Sabrina","MacLean, Robert","Huh, Jin-Hyeun","Scales, Damon C","Neilipovitz, David"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32458267","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s12630-020-01713-5","keywords":["covid-19","conservation strategies","drug shortage","pandemic","therapeutic alternatives"],"topics":["Treatment"],"weight":1,"_version_":1668141322672799745,"score":51.105732}]}